Copyright 2024 All rights reserved.

Pipelines

Stem Medicare is developing EV-based new drugs for various diseases

as well as regenerative medicines based on the world's only non-immunogenic,

immune-tolerized extracellular vesicle technology.

Pipelines

Atopic Dermatitis

Atopic dermatitis is a type of autoimmune disease in which our immune cells cause hyperimmune reactions and destroy our own healthy tissues, including the heart, brain, nerves, muscles, skin, eyes, joint, lungs, kidneys, and blood vessels. Since the clinical phenotypes of atopic dermatitis vary greatly by race, age, and region, there is still no treatment that can be applied to all clinical phenotypes of atopic dermatitis.
The extracellular vesicle therapeutics (MBTC-AD-EVs) developed by Stemmedicare for the treatment of atopic dermatitis have the advantage of maintaining the homeostasis of the Th1/Th2 immune responses and being applicable regardless of the Th1/Th2/Th17/Th22 phenotype. Therefore, the indications of MBTC-AD-EVs are expected to be expanded as new therapeutics that can cure all autoimmune diseases (asthma, rheumatoid arthritis, Crohn's disease, type I diabetes, etc.) including atopic dermatitis.

Mode of Action (MOA)

Promotion of
differentiation to
non-autoreactive
regulatory T cells

In vitro Assay

Inhibition of T cell
proliferation &
Induction of regulatory
T cell differentiation

In vivo Assay

Clinical Trials of
RETROPHA-G Cream
containing
MBTC-AD-EVs
Evaluation of improvement effects of skin barrier strengthening and itching relief due to dry skin performed by Korea Testing & Research Institute (n=22)
  • Skin Itch Improvement Rate
    VAS (Visual Analogue Scale)

    Skin itch was significantly decreased after
    4 weeks RETROPHA-G Cream
    use as compared with before use.

  • Skin Moisturizing Improvement Rate
    Corneometer

    The skin moisturizing was significantly
    increased after 4 weeks RETROPHA-G
    Cream use as compared with before use

Evaluation of the efficacy and safety of RETROPHA-G Cream on atopic dermatitis performed
by Cheonan Oriental Hospital of Daejeon University (n=30, 4 weeks use)
  • Skin Itch
    Improvement Rate
  • EASI Score
    Decrease Rate
  • Skin Moisturizing
    Improvement Rate
  • Serum IgE

    Decrease Rate
MBTC-AD-EVs

  • Immune-tolerized extracellular vesicle
    therapeutics for atopic dermatitis

  • Instant skin itching relief and
    skin barrier strengthening effects

  • Applicable to all clinical phenotypes of atopic
    dermatitis due to innovative MOA of
    promoting differentiation to non-autoreactive
    regulatory T cells

  • Applicable to atopic dermatitis of all ages and

    grades without any side-effect

  • Applicable to the treatment of all autoimmune
    diseases including atopic dermatitis

  • New Excellent Technology (NET) Certificated